ABIM MOC

All Hands on Deck: A Focus on Current and Emerging Treatment Options in the Frontline Setting for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…

All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

 Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…

Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…

Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

 Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…

All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and Equity Strategies to Improve Patient Lives

The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies…

All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…

Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial…

ADCs in HR+/HER2- mBC: Managing AEs

Patients with HR-positive/HER2-negative metastatic breast cancer (mBC) who receive antibody-drug conjugates (ADCs) have a unique spectrum of adverse events (AEs) that can lower quality of life (QoL). Patients and caregivers rely on health care providers for…